6817 Stock Overview
Winston Medical Supply Co.,Ltd. develops, manufactures, and distributes pharmaceuticals, nutrition supplements, and cosmeceutical products.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Winston Medical Supply Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$129.00 |
| 52 Week High | NT$145.00 |
| 52 Week Low | NT$75.90 |
| Beta | 0.11 |
| 1 Month Change | 4.03% |
| 3 Month Change | 28.36% |
| 1 Year Change | 67.53% |
| 3 Year Change | 10.73% |
| 5 Year Change | n/a |
| Change since IPO | 101.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6817 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -0.4% | -2.2% | -1.6% |
| 1Y | 67.5% | 7.2% | 25.9% |
Price Volatility
| 6817 volatility | |
|---|---|
| 6817 Average Weekly Movement | 6.6% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.6% |
| 10% least volatile stocks in TW Market | 2.2% |
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1974 | n/a | n/a | www.winston.com.tw |
Winston Medical Supply Co.,Ltd. develops, manufactures, and distributes pharmaceuticals, nutrition supplements, and cosmeceutical products. It offers sterile ophthalmic preparations comprising gels, suspensions, solutions, and emulsions; hormone preparations, which primarily cover birth control and oral suspension for cancer related cachexia; external use preparations comprising ointments; and other oral preparations, which are in oral dosage forms, such as powders, troches, tables, film coated tablets, chewables, and capsules for the treatment of colds, gastrointestinal issues, or other indications.
Winston Medical Supply Co., Ltd. Fundamentals Summary
| 6817 fundamental statistics | |
|---|---|
| Market cap | NT$2.38b |
| Earnings (TTM) | NT$158.76m |
| Revenue (TTM) | NT$709.07m |
15.0x
P/E Ratio3.4x
P/S RatioIs 6817 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6817 income statement (TTM) | |
|---|---|
| Revenue | NT$709.07m |
| Cost of Revenue | NT$361.48m |
| Gross Profit | NT$347.60m |
| Other Expenses | NT$188.84m |
| Earnings | NT$158.76m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 8.62 |
| Gross Margin | 49.02% |
| Net Profit Margin | 22.39% |
| Debt/Equity Ratio | 11.7% |
How did 6817 perform over the long term?
See historical performance and comparison